All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Thomas MacGillivray, MD

Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion,: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Avania/Cellphire: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Portrero Med Inc: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 28, 2022)

Presentations

1. Five Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low-Risk Randomized Trial
   Michael Mack, MD
   Disclosure(s): Carmat: Corporate Board Member (Ongoing); Edwards Lifesciences: Trial Co-PI (Ongoing); Medtronic: Study Chair (Ongoing)
    
2. Four Year Outcomes from the EVOLUT Low Risk Trial
   Michael J. Reardon, MD
   Disclosure(s): AstraZeneca; Boston Scientific; Cook Medical; Ethicon; Merck & Co., Inc., Rahway, NJ, USA; Novartis; BMS: Consultant (Ongoing)
    
3. Survival after SAVR in Low-Risk Patients: A Contemporary Trial Benchmark
   Vinay Badhwar, MD
    
4. Late Breaking: Five Year Clinical and Echocardiographic Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial
   Vinod H. Thourani, MD
   Disclosure(s): Abbott Vascular: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AtriCure: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); dasi simulations: Advisory Board (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Jenavalve: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
    
5. Panel Discussion and Audience Q&A